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OBJECTIVES We compared catheter-based electromechanical mapping (NOGA system, Biosense-
Webster, Haifa, Israel) with positron emission tomography (PET) and single photon
emission computed tomography (SPECT) for prediction of reversibly dysfunctional myocar-
dium (RDM) and irreversibly dysfunctional myocardium (IDM) in patients with severe left
ventricular dysfunction. Furthermore, we established the optimal discriminatory value of
NOGA measurements for distinction between RDM and IDM.
BACKGROUND The NOGA system can detect viable myocardium but has not been used for prediction of
post-revascularization contractile function in patients with ischemic cardiomyopathy.
METHODS Twenty patients (19 males, age [mean SD] 60 16 years, ejection fraction [EF] 29 6%)
underwent viability testing with NOGA and PET or SPECT before revascularization. Left
ventricular function was studied at baseline and six months after revascularization.
RESULTS The EF increased to 34  13% at six months (p  0.05 vs. baseline). The 58 RDM and 57
IDM regions differed with regard to unipolar voltage amplitude (UVA) (9.2 3.9 mV vs. 7.6
 4.0 mV, p  0.05), normalized UVA (106  54% vs. 75  39%, p  0.05), and tracer
uptake (76 17% vs. 60 20%, p 0.05). The NOGA local shortening did not distinguish
between RDM and IDM (6.4  5.8% vs. 5.4  6.6%). By receiver operating characteristic
curve analysis, myocardial tracer uptake had better diagnostic performance than UVA (area
under curve [AUC]  SE: 0.82  0.04 vs. 0.63  0.05, p  0.05) and normalized UVA
(AUC  SE: 0.70  0.05, p  0.05). Optimal threshold was defined as the value yielding
sensitivity specificity for prediction of RDM. Sensitivity and specificity were 59% at a UVA
of 8.4 mV, 65% at a normalized UVA of 83%, and 78% at a tracer uptake of 69%.
CONCLUSIONS The NOGA system may discriminate RDM from IDM with optimal discriminatory values
for UVA and normalized UVA of 8.4 mV and 83%, respectively. However, the diagnostic
performance does not reach the level obtained by PET and SPECT in patients with severe
heart failure. (J Am Coll Cardiol 2003;41:843–8) © 2003 by the American College of
Cardiology Foundation
Catheter-based electromechanical mapping (1,2) can detect
viable myocytes in dysfunctional myocardium of patients
with ischemic heart disease and mildly reduced left ventric-
ular (LV) function (3–5). In these patients, measures of
regional electrical and contractile function correlate with
myocardial metabolic activity, membrane integrity, and
perfusion as assessed by positron emission tomography
(PET) and single photon emission computed tomography
(SPECT) (3–6). Electromechanical mapping can also pre-
dict recovery of contractile function after revascularization
of infarct zones in patients with nearly normal LV function
(6). The advantage of electromechanical mapping is the
potential use in the catheterization laboratory allowing ad
hoc percutaneous coronary intervention (PCI) guided by
viability assessment. The drawbacks of the method are its
invasive nature with the potential risk of embolization of LV
thrombus material and of hemorrhagic pericardial effusion,
as well as the variability of measurements that complicates
distinction between viable and nonviable myocardium (7).
In patients with severely reduced LV function, we have
previously found that absolute and normalized unipolar
voltage amplitude (UVA) levels distinguish between myo-
cardial regions with and without evidence of viable myocytes
as assessed by PET (7). However, the diagnostic perfor-
mance of electromechanical mapping for prediction of
reversible myocardial dysfunction has not been compared
with PET and SPECT by post-revascularization follow-up.
Furthermore, the optimal discriminatory value of electro-
mechanical mapping measurements for the distinction be-
tween reversibly dysfunctional myocardium (RDM) and
irreversibly dysfunctional myocardium (IDM) has not been
established.
The purposes of the present study were to: 1) compare the
ability of electromechanical mapping and PET and SPECT
to discriminate between myocardium with and without
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post-revascularization recovery of function in patients
with severe heart failure, and 2) identify the optimal
threshold value of electromechanical mapping measure-
ments for the prediction of post-revascularization myo-
cardial function.
METHODS
Patients. We studied 20 patients with ischemic heart
disease verified by significant coronary artery obstruction by
coronary angiography and an ejection fraction (EF) 40%.
Exclusion criteria included peripheral vascular disease, aor-
tic stenosis, unstable ischemic syndrome, and LV thrombus
on echocardiography or magnetic resonance imaging
(MRI). Informed consent was obtained from all patients.
Six patients were previously included in a study evaluating
the NOGA system (Biosense-Webster, Haifa, Israel) map-
ping versus PET (7). The local ethics committee approved
the study.
Study protocol. Before revascularization, the patients un-
derwent viability assessment by NOGA electromechanical
mapping and 18F-fluorodeoxyglucose (FDG) PET or 99mTc-
sestamibi SPECT. Regional and global LV function were
assessed before and six months after revascularization by paired
three-dimensional echocardiographic or MRI studies.
Electromechanical mapping. The electromechanical
mapping system NOGA has been described in detail
previously (1,2,7). We used a direct retrograde left-sided
approach through the femoral artery. The mapping catheter
was advanced under fluoroscopic guidance to the LV. Points
outlining the boundaries of the LV (apex, aortic outflow,
mitral inflow) were acquired with fluoroscopic guidance.
These hallmarks minimized rotational and horizontal mis-
alignment in the construction of the polar maps that were
used for comparison between the different imaging modal-
ities. Unipolar signals filtered at 0.5 to 400 Hz were
recorded in this study, and maps of UVA were obtained by
displaying the peak-to-peak amplitudes. From the mechan-
ical data, regional contractility was obtained by the use of
the linear endocardial local shortening (LS) formula: LS(p)
 [Li(ED)  Li(ES)/Li(ED)]  100, where LS (p) denotes
the weighted average LS of a point (p) relative to all its
endocardial neighboring points, and Li(ED) and Li(ES) are
the distances of an index point from its neighbors at
end-diastole and end-systole, respectively. The LS(p) value
is a ratio that becomes smaller or even negative if regional
contractility is reduced or becomes paradoxical. We ac-
quired points only when the catheter tip was stable on the
endocardium using location stability, loop stability, and
cycle-length stability as specified by the manufacturer
(1,2,7). Subsequently automatic editing was performed to
remove internal points and points with unsatisfactory sta-
bility using moderate filtering. The UVA and linear endo-
cardial LS were registered as previously described (7).
Endocardial sites were in total divided into nine segments
for comparative analysis with echocardiographic and PET
imaging data (7). Normalized UVA were obtained as the
percentage of the mean value of all control segments in each
patient. This could not be performed in four patients who
had no regions with normal wall motion score.
Nuclear cardiologic methods. We determined regional
myocardial tracer uptake by FDG PET (11 patients) and
99mTc-sestamibi SPECT (9 patients). The PET studies
were conducted under a hyperinsulinemic, euglycemic (5
mmol/l) clamp (Actrapid; Novo Nordisk, Gentofte, Den-
mark) with 40 mU/min/m2 body surface area starting 1.5 h
before the FDG scan. All subjects were scanned in two
dimensions with an ECAT EXACT HR whole-body
scanner (CTI/Siemens, Knoxville, Tennessee) with an axial
field of view of 15 cm. A volume of 370 MBq FDG was
injected, and 50 min later a static 10-min frame was
acquired (7,8). Nine regions were defined to match the
echocardiographic and the electromechanical regions (7).
The FDG image was scaled to give the value of 100% in the
region with maximal tracer uptake.
99mTc-sestamibi (700 MBq 10%) was injected after the
patient had been resting for 30 min, and image acquisition
was started 30 min after radioisotope injection. The
SPECT acquisition was performed using a dual-headed
rotating gamma camera (ADAC, Milpitas, Connecticut)
with a high-resolution, parallel-holed collimator. Sixty-four
projections of 25 s each were obtained over a non-circular
180° arc, extending from the 45° right anterior oblique to
the 45° left posterior oblique position. No attenuation or
scatter correction was used. Images were analyzed with the
automatic quantitative program AutoQUANT (Cedars-
Sinai Medical Center, Los Angeles, California) (9) and
matched to the echocardiographic and the electromechani-
cal regions. Images were scaled to give the value of 100% in
the region with maximal tracer uptake. The PET and
SPECT images were reoriented and aligned to MRI and
echocardiographic studies by using the insertion of the right
ventricle as a landmark.
Abbreviations and Acronyms
AUC  area under curve
EF  ejection fraction
FDG  18F-fluorodeoxyglucose
IDM  irreversibly dysfunctional myocardium
LS  local shortening
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MRI  magnetic resonance imaging
PCI  percutaneous coronary intervention
PET  positron emission tomography
RDM  reversibly dysfunctional myocardium
ROC  receiver operating characteristic
SPECT  single photon emission computed
tomography
UVA  unipolar voltage amplitude
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Assessment of regional and global LV function.
Evaluation of regional and global LV function was done
with echocardiography (11 patients) and MRI (9 patients).
We performed transthoracic three-dimensional echocardi-
ography by apical rotation with tissue harmonic imaging
using a 2.5-MHz transducer mounted in a hand-held
rotation device (Vingmed System Five, GE-Vingmed Ul-
trasound, Horten, Norway) (10). The resulting two-
dimensional, long-axis images were stored as digital cine
loops in a computer for off-line analysis and generation of a
three-dimensional image (Echo-Pac software, GE-
Vingmed Ultrasound, Horten, Norway).
The MRI investigation was performed on a 1.5-T whole
body system (Gyroscan ACS-NT 15, Philips Medical
Systems, Best, The Netherlands). The subjects were exam-
ined in the supine position. A breath hold fast echo
sequence with echo planar imaging was used to acquire a
stack of eight to nine parallel and equidistant short-axis
images that included the LV from base to apex. The slice
selection was defined from an arbitrary starting point (10).
The LV volumes were calculated according to echocar-
diography and MRI by manual tracing of endocardial
borders at end-diastole and end-systole as previously de-
scribed (10). Wall motion analysis using a nine-segment
model was performed by consensus of two observers who
were blinded to the viability data. Myocardial regions were
graded as follows: 1) control regions with normal wall
motion score before revascularization; 2) reversibly dysfunc-
tional regions with recovery of function at follow-up by 1
wall motion score; or 3) irreversibly dysfunctional regions
without recovery of function at follow-up.
Coronary angiography. Coronary angiography was per-
formed through the femoral artery. We assessed location of
stenoses and graded mean luminal diameter stenosis visually
(diameter stenosis 50% was considered significant).
Follow-up six months after revascularization did not iden-
tify any occluded target vessels.
Statistical analysis. Data are presented as mean  SD or
median (25th to 75th percentile) unless otherwise indicated.
We used the statistical software program SPSS 10.0 (SPSS
Inc., Cary, North Carolina) for statistical analyses. The
Kolmogorov-Smirnov test was used as a test of normality
and was used to compare characteristics of reversibly and
irreversibly dysfunctional regions. Comparison of left ven-
tricular ejection fraction (LVEF) and volumes before and
after revascularization was done by paired t test. Student t
test was used to compare wall motion scores at baseline in
segments with and without recovery and patient character-
istics between patients undergoing PET and SPECT. Receiver
operating characteristic (ROC) curve analysis was performed
to compare the diagnostic performance of the different modal-
ities studied for discrimination between RDM and IDM (11).
Area under curves (AUC) were compared as described by
Hanley and McNeil (11) using the statistical software program
GraphROC (GraphROC, Turku, Finland). A value of p 
0.05 was considered significant.
RESULTS
Patient characteristics. Among the 20 patients studied, 19
were males with mean age of 60 16 years. The EF was 29
 6% (range 15% to 40%). Three patients had no clinical
history of previous acute myocardial infarction, but they all
displayed severe wall motion abnormalities on echocardiog-
raphy. The median time interval from infarction to revas-
cularization was 1 year (range 2 months to 20 years). Two
patients had previously undergone revascularization. Five
patients had one-vessel disease, 3 had two-vessel disease,
and 12 had three-vessel disease. Left main coronary artery
disease was present in two patients. Revascularization was
performed by coronary artery bypass grafting in 11 patients
and PCI in 9. Median time interval from NOGA and
PET/SPECT to revascularization was 24 and 54 days,
respectively. No cardiac events occurred between inclusion
in the study, viability tests, revascularization, and follow-up
at 184  69 days. The EF increased to 34  13% at
follow-up (p  0.05 vs. baseline), whereas LV end-diastolic
volumes did not differ (202  42 ml vs. 209  59 ml, p 
0.51).
There were no differences between patients undergoing
PET and SPECT with regard to age (60 8 years vs. 63
7 years), LVEF (30 7 % vs. 28 7 %), extent of coronary
artery disease (2 [2 to 3] vs. 3 [2 to 3] diseased vessels), or
co-morbidities.
Electromechanical mapping procedural characteristics.
We sampled 74  20 points per patient, of which 50  18
points fulfilled the stability criteria after moderate filtering.
In 13 regions, satisfactory mapping data were not available
because 3 points were sampled during the procedure.
Mapping time was 45  10 min.
Regional characteristics. Among the 180 regions, 28 dis-
played normal wall motion score (control regions) and 152
were dysfunctional. We excluded 13 regions with missing
electromechanical data and 24 regions that were unrevascu-
larized. Among 115 dysfunctional regions in the final
analysis, recovery of function was observed in 58, whereas
57 were irreversibly dysfunctional. Among the 11 patients
undergoing coronary artery bypass grafting, a total of 36 of
76 dysfunctional segments (47%) displayed reversible myo-
cardial dysfunction. In the nine patients undergoing PCI,
22 of 39 dysfunctional segments (56%) recovered function at
follow-up. There was no statistical difference in the likeli-
hood of recovery in dysfunctional segments among the two
groups (p  0.37). Wall motion score before revasculariza-
tion did not differ between segments with and without
functional recovery (2.3  0.6 and 2.5  0.5, p  0.18).
Accordingly, LS was not different in the two types of
regions (Table 1). Reversibly dysfunctional regions had
higher UVA, normalized UVA, and tracer uptake than
irreversibly dysfunctional regions, whereas LS was similar
(Table 1). Control regions had higher LS than dysfunc-
tional regions, and similar UVA, normalized UVA, and
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tracer uptake as in reversibly dysfunctional regions. There
were no differences between FDG and 99mTc-sestamibi
uptake in control, reversibly dysfunctional or irreversibly
dysfunctional regions (Table 1).
Comparison between electromechanical mapping and
PET/SPECT. The ROC curve analysis showed that for
prediction of functional outcome in dysfunctional myocar-
dium after revascularization, myocardial tracer uptake
(AUC  SE, 0.76  0.05) was superior to UVA (AUC 
SE, 0.64  0.05, p  0.05 vs. tracer uptake). In patients
with control regions available for normalization of UVA,
this approach tended to improve the diagnostic accuracy of
electromechanical mapping compared with absolute UVA
(Fig. 1) (AUC  SE; 0.70  0.05 vs. 0.63  0.05; p 
0.09). Tracer uptake remained the best predictor of func-
tional outcome after revascularization in these patients
(AUC  SE; 0.82  0.04; p  0.05 vs. normalized UVA).
Subgroup ROC curve analysis in patients studied with
either PET or SPECT revealed similar AUC (AUC  SE;
0.81 0.06 vs. 0.84 0.07) for the two nuclear cardiologic
methods.
The optimal cutoff value for distinction between RDM
and IDM was 68% for FDG uptake and 71% for 99mTc-
sestamibi (p  NS).
Prediction of recovery of LV function by electromechan-
ical mapping and PET/SPECT at different threshold
criteria for viability. The sensitivity and specificity for the
distinction between RDM and IDM are shown at various
thresholds of UVA, normalized UVA, and tracer uptake in
Figures 2A to 2C. The selection of the optimal threshold
value depends on the consequences of false positive and false
negative test results, but the proportion of correctly classi-
fied cases, efficiency, is often highest when sensitivity 
specificity. Sensitivity and specificity was 59% at an UVA of
8.4 mV, 65% at a normalized UVA of 83%, and 78% at a
tracer uptake of 69%.
DISCUSSION
The present study establishes that catheter-based mapping
of regional myocardial electrical function can discriminate
between RDM and IDM in patients with severe LV
dysfunction. However, the diagnostic performance of this
modality does not reach the level obtained with PET and
SPECT.
Mapping of regional electrical function for prediction of
contractile status after revascularization. The potential of
endocardial electromechanical mapping for the prediction of
post-revascularization recovery of LV function in patients










UVA (mV) 8.2 (5.1–12.8) 8.9 (6.5–12.2) 6.9 (4.9–9.7)*
9.1  4.3 9.4  4.0 7.7  3.8
LS (%) 8.8 (6.4–12.4)† 6.8 (2.5–10.1) 6.5 (2.9–9.4)
7.0  4.8 6.0  5.4 6.0  6.3
Tracer uptake (%) 88 (84–100) 79 (68–92) 58 (50–78)‡
89  12 79  15 61  20
FDG uptake (%) 100 (87–100) 77 (63–87) 57 (49–70)‡
(11 patients) 91  10 (n  15) 77  14 (n  29) 60  17 (n  36)
99mTc-sestamibi (%) 85 (73–100) 83 (72–94) 60 (50–84)‡
(9 patients) 87  14 (n  13) 81  15 (n  29) 63  25 (n  21)
Normalized UVA (%) 100 (78–113) 94 (72–133) 64 (54–97)‡
96  24 106  54 77  37
Median (25th percentile to 75th percentile) and mean  SD. *p  0.02 vs. reversibly dysfunctional and control regions; †p 
0.05 vs. dysfunctional regions; ‡p  0.001 vs. reversibly dysfunctional and control regions. There were no differences between
FDG and 99mTc-sestamibi uptake in control, reversibly, and irreversibly dysfunctional regions, respectively.
FDG  18F-fluorodeoxyglucose; LS  local shortening; UVA  unipolar voltage amplitude.
Figure 1. The receiver operating characteristics curve for the distinction
between dysfunctional myocardium with and without functional recovery at
follow-up. Tracer uptake had better test characteristics (solid line; area
under curve [AUC]  SE, 0.82  0.04) than normalized unipolar voltage
amplitude (UVA) (dashed line; AUC  SE, 0.70  0.05, p  0.05 vs.
tracer uptake) and absolute UVA (dotted line; AUC  SE, 0.63  0.05,
p 0.05 vs. tracer uptake). Normalization of UVA tended to improved the
diagnostic accuracy of electromechanical mapping (p  0.09 vs. UVA).
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with ischemic cardiomyopathy has not previously been
established by postoperative follow-up. Koch et al. (6)
reported a sensitivity of 91% and a specificity of 71% for
prediction of reversible myocardial dysfunction at an UVA
threshold of 7.5 mV. In the present study, the same
threshold yielded a sensitivity of 69% and a specificity of
52%. The different test characteristics may be explained by
differences between the patient populations studied, because
the subjects studied by Koch et al. (6) had preserved LV
function with a mean EF of 49% and were predominantly
one-vessel diseased. Extensive infarction, fibrosis, LV dila-
tion, and remodeling affect the electrical properties of the
myocardium (12) and can account for different electrical
properties of RDM and IDM in patients with and without
preserved LV function. Differences in regional electrical
activities can be reduced by the far-field component of UVA
(13); such differences could also explain why regional UVA
in control regions were lower and the overlap between UVA
in reversibly and irreversibly dysfunctional regions was
greater in our patients than in patients with relatively
preserved systolic function (3–6). The optimal discrimina-
tory value of electromechanical mapping measurements for
the distinction between RDM and IDM was higher than
predicted from comparison with PET and SPECT in
studies without postoperative follow-up (3–7), possibly
because of the known overestimation of viability by nuclear
techniques compared with functional recovery after revas-
cularization (14). In the study by Botker et al. (7), optimal
diagnostic thresholds of electromechanical mapping for the
detection of PET-viable segments were 6.5 mV and 68%,
but no follow-up data on LV function were available. The
higher diagnostic threshold observed in the present study is
likely due to the use of recovery of LV function as an
outcome measure. Positron emission tomography and
SPECT are sensitive but not specific for the prediction of
post-revascularization recovery of LV function (8,14), and
positive predictive values are on average 70% to 75% (14).
This is due to a considerable part of PET/SPECT-viable
segments not regaining contractile function after revascu-
larization because of remodeling and subendocardial scar-
ring (15).
Electromechanical mapping versus nuclear cardiologic
methods in the prediction of RDM and IDM. The
diagnostic performance of electromechanical mapping ap-
peared less efficient than PET/SPECT as assessed by ROC
curve analysis of UVA compared with tracer uptake. The
difference between the areas under the ROC curves reflects
a larger overlap of electrical activity than tracer uptake in
regions with reversible and irreversible myocardial dysfunc-
tion. Measures to reduce the variability of electrical mea-
surements, therefore, will increase the diagnostic accuracy of
regional UVA. As previously suggested (7), normalization
of UVA improved the diagnostic characteristics of electrical
mapping. Even so, electromechanical mapping did not
reach the same diagnostic performance as the nuclear
cardiologic methods. Achievement of a higher point density
by the sampling of more points may reduce variability and
improve the diagnostic characteristics, but it requires a
longer mapping time. Analysis of endocardial impedance
and unipolar signal slew rate does not increase the ability of
endocardial mapping to detect scar tissue (16). In its present
form, the NOGA system is useful for regional viability
assessment in patients without severe LV dysfunction (3–7),
although this has limited clinical implications.
Figure 2. Sensitivity and specificity for the distinction between reversibly
dysfunctional myocardium (RDM) and irreversibly dysfunctional myocar-
dium are shown at various thresholds of (A) unipolar voltage amplitude
(UVA), (B) normalized UVA, and (C) tracer uptake. Optimal threshold
was defined as the value yielding sensitivity  specificity for the prediction
of RDM. Sensitivity and specificity were 59% at a UVA of 8.4 mV, 65%
at a normalized UVA of 83%, and 78% at a tracer uptake of 69%.
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Mapping of linear endocardial LS. The LS obtained by
the NOGA system has been reported to differ between
regions with and without evidence of viable myocytes as
assessed by PET or SPECT (3–6). In our study population
of patients with severe LV dysfunction, wall motion scores
and local mechanical function did not differ in reversibly and
irreversibly dysfunctional regions, a common observation in
patients with ischemic cardiomyopathy (8). Mapping of
regional contractile function in these patients discriminated
between regions with preserved and reduced contractility,
and together with mapping of electrical function, this allows
NOGA-guided therapeutic interventions (17). Thus,
NOGA is an excellent intracardial navigation system, but its
potential appears much greater for therapeutic than for
diagnostic purposes.
Study limitations. Our comparison between NOGA and
either PET or SPECT may be impaired by different
diagnostic characteristics of the two nuclear cardiologic
methods. However, subgroup ROC curve analysis in pa-
tients studied with either of these modalities revealed
similar AUC, suggesting that the diagnostic characteristics
did not differ. In addition, there were no differences between
FDG and 99mTc-sestamibi uptake in control, reversibly
dysfunctional or irreversibly dysfunctional regions. These
similarities between SPECT and PET are predictable
because of the known correlation between myocardial
99mTc-sestamibi and FDG uptake (14,18).
Conclusions. In patients with severe LV dysfunction,
catheter-based mapping of regional UVA can differentiate
between RDM and IDM. However, the diagnostic perfor-
mance does not reach the level obtained by PET and
SPECT which also have the advantage that they are
non-invasive modalities with negligible complication risks.
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